Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers

Mehdi Sanati; Christian G. Figueroa-Espada; Emily L. Han; Michael J. Mitchell; Saber Amin Yavari

doi:10.1021/acsnano.4c11259

Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers

Mehdi Sanati, Christian G. Figueroa-Espada, Emily L. Han, Michael J. Mitchell^*, Saber Amin Yavari^*

^*Corresponding author for this work

Regenerative Medicine and Stem Cells

Research output: Contribution to journal › Review article › peer-review

Abstract

Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.

Original language	English
Pages (from-to)	34425–34463
Number of pages	39
Journal	ACS Nano
Volume	18
Issue number	51
Early online date	12 Dec 2024
DOIs	https://doi.org/10.1021/acsnano.4c11259
Publication status	Published - 24 Dec 2024

Keywords

cancer
chemoresistance
chemotherapy
drug delivery
gene therapy
nanoparticles
nanotechnology
siRNA

Access to Document

10.1021/acsnano.4c11259

Cite this

@article{68c959032eee4bd992b485b6cb2692e2,

title = "Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers",

abstract = "Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.",

keywords = "cancer, chemoresistance, chemotherapy, drug delivery, gene therapy, nanoparticles, nanotechnology, siRNA",

author = "Mehdi Sanati and Figueroa-Espada, {Christian G.} and Han, {Emily L.} and Mitchell, {Michael J.} and Yavari, {Saber Amin}",

note = "Publisher Copyright: {\textcopyright} 2024 American Chemical Society.",

year = "2024",

month = dec,

day = "24",

doi = "10.1021/acsnano.4c11259",

language = "English",

volume = "18",

pages = "34425–34463",

journal = "ACS Nano",

issn = "1936-0851",

publisher = "American Chemical Society",

number = "51",

}

TY - JOUR

T1 - Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers

AU - Sanati, Mehdi

AU - Figueroa-Espada, Christian G.

AU - Han, Emily L.

AU - Mitchell, Michael J.

AU - Yavari, Saber Amin

PY - 2024/12/24

Y1 - 2024/12/24

N2 - Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.

AB - Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.

KW - cancer

KW - chemoresistance

KW - chemotherapy

KW - drug delivery

KW - gene therapy

KW - nanoparticles

KW - nanotechnology

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85211993198&partnerID=8YFLogxK

U2 - 10.1021/acsnano.4c11259

DO - 10.1021/acsnano.4c11259

M3 - Review article

AN - SCOPUS:85211993198

SN - 1936-0851

VL - 18

SP - 34425

EP - 34463

JO - ACS Nano

JF - ACS Nano

IS - 51

ER -

Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this